Anti-Tumor Effects of Anti-CD20 Chimeric Antigen Receptor Therapy in Canine B Cell Lymphoma Patients

被引：2
|
作者：
Panjwani, M. Kazim [1 ]
Gnanandarajah, Josephine S. [1 ]
MaloneyHuss, Martha A. [1 ]
Mason, Nicola J. [1 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
来源：
MOLECULAR THERAPY | 2016年 / 24卷
关键词：
D O I：
10.1016/S1525-0016(16)33558-4
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
750
引用
收藏
页码：S296 / S296
页数：1
相关论文
共 50 条
  • [21] Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients
    D. Wang
    C. Zeng
    B. Xu
    J.-H. Xu
    J. Wang
    L.-J. Jiang
    Q.-X. Wang
    C.-R. Li
    N. Wang
    L. Huang
    Y.-C. Zhang
    Y. Xiao
    J.-F. Zhou
    [J]. Blood Cancer Journal, 10
  • [22] Quality of life in patients with B-cell lymphoma during maintenance therapy with the Anti-CD20 antibody rituximab
    Witzens-Harig, Mathias
    Heiss, Christiane
    Benner, Axel
    Hensel, Manfred
    Neben, Kai
    Dreger, Peter
    Kraemer, Alwin
    Ho, Anthony D.
    [J]. BLOOD, 2007, 110 (11) : 189B - 189B
  • [23] Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma
    Lim, Sean H.
    Levy, Ronald
    [J]. JOURNAL OF IMMUNOLOGY, 2014, 193 (04): : 1519 - 1524
  • [24] Characterization of a novel anti-CD20 Stradobody™ with potent in vitro anti-tumor activity
    Zhang, Xiaoyu
    Burch, Erin
    Chen, Shaodong
    Sallin, Michelle
    Olsen, Henrik
    Block, David
    Strome, Scott
    [J]. JOURNAL OF IMMUNOLOGY, 2014, 192
  • [25] Sequential anti-CD19, anti-CD22, and anti-CD20 autologous chimeric antigen receptor T cell (CAR-T) therapies treating a child with relapsed refractory Burkitt lymphoma
    Du, Juan
    Zhang, Yonghong
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [26] Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with Rituximab, a chimeric Anti-CD20 monoclonal antibody
    Soda, R
    Costanzo, A
    Cantonetti, M
    Orlandi, A
    Bianchi, L
    Chimenti, S
    [J]. ACTA DERMATO-VENEREOLOGICA, 2001, 81 (03) : 207 - 208
  • [27] Chimeric antigen receptor-T cell, a novel player in anti-tumor treatment
    Ni, Jieming
    Ni, Anping
    [J]. TRANSLATIONAL CANCER RESEARCH, 2018, 7 (04) : 1143 - 1150
  • [28] An easy way to make a good anti-tumor chimeric antigen receptor T cell?
    Muranski, Pawel
    [J]. CYTOTHERAPY, 2014, 16 (05) : 577 - 578
  • [29] Peripheral T-cell lymphoma after anti-CD20 antibody therapy
    Tetreault, S
    Abler, SL
    Robbins, B
    Saven, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) : 1635 - 1636
  • [30] Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma
    Heinzerling, LM
    Urbanek, M
    Funk, JO
    Peker, S
    Bleck, O
    Neuber, K
    Burg, G
    von den Driesch, P
    Dummer, R
    [J]. CANCER, 2000, 89 (08) : 1835 - 1844
12345